The tweet was deleted by the author.
But we saved everything 🙂.
Outlook Therapeutics has successfully closed a public offering, raising 5.0 million dollars.
The company aims to strengthen its financial position with the additional capital. The proceeds from the offering are expected to support ongoing operations and future strategic initiatives.
Outlook Therapeutics recently announced a proposed public offering to raise new capital in support of its ongoing strategy and growth. The company has also issued updates following meetings with the FDA on ONS-5010, outlining its development pathway for retinal disease treatment, according to a prior statement. These efforts reflect a continued focus on advancing its clinical and financial objectives.